Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells.

O'Connell MP, Fiori JL, Kershner EK, Frank BP, Indig FE, Taub DD, Hoek KS, Weeraratna AT.

J Biol Chem. 2009 Oct 16;284(42):28704-12. doi: 10.1074/jbc.M109.028498. Epub 2009 Aug 20.

2.

Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced melanoma cell motility.

Camilli TC, Xu M, O'Connell MP, Chien B, Frank BP, Subaran S, Indig FE, Morin PJ, Hewitt SM, Weeraratna AT.

Pigment Cell Melanoma Res. 2011 Feb;24(1):175-86. doi: 10.1111/j.1755-148X.2010.00792.x. Epub 2010 Dec 1.

3.

WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells.

Ekström EJ, Bergenfelz C, von Bülow V, Serifler F, Carlemalm E, Jönsson G, Andersson T, Leandersson K.

Mol Cancer. 2014 Apr 26;13:88. doi: 10.1186/1476-4598-13-88.

4.

Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.

Reiland J, Sanderson RD, Waguespack M, Barker SA, Long R, Carson DD, Marchetti D.

J Biol Chem. 2004 Feb 27;279(9):8047-55. Epub 2003 Nov 20.

5.

Wnt5A activates the calpain-mediated cleavage of filamin A.

O'Connell MP, Fiori JL, Baugher KM, Indig FE, French AD, Camilli TC, Frank BP, Earley R, Hoek KS, Hasskamp JH, Elias EG, Taub DD, Bernier M, Weeraratna AT.

J Invest Dermatol. 2009 Jul;129(7):1782-9. doi: 10.1038/jid.2008.433. Epub 2009 Jan 29.

6.

The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma.

O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, French AD, Dissanayake SK, Indig FE, Bernier M, Taub DD, Hewitt SM, Weeraratna AT.

Oncogene. 2010 Jan 7;29(1):34-44. doi: 10.1038/onc.2009.305. Epub 2009 Oct 5.

7.

Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.

Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM.

Cancer Cell. 2002 Apr;1(3):279-88.

8.

Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration.

Schwartz AL, Malgor R, Dickerson E, Weeraratna AT, Slominski A, Wortsman J, Harii N, Kohn AD, Moon RT, Schwartz FL, Goetz DJ, Kohn LD, McCall KD.

Clin Cancer Res. 2009 Jun 15;15(12):4114-22. doi: 10.1158/1078-0432.CCR-09-0005. Epub 2009 May 26.

9.

The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition.

Dissanayake SK, Wade M, Johnson CE, O'Connell MP, Leotlela PD, French AD, Shah KV, Hewitt KJ, Rosenthal DT, Indig FE, Jiang Y, Nickoloff BJ, Taub DD, Trent JM, Moon RT, Bittner M, Weeraratna AT.

J Biol Chem. 2007 Jun 8;282(23):17259-71. Epub 2007 Apr 10.

10.

A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion.

Jenei V, Sherwood V, Howlin J, Linnskog R, Säfholm A, Axelsson L, Andersson T.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19473-8. doi: 10.1073/pnas.0909409106. Epub 2009 Nov 9.

11.

WNT5A expression increases during melanoma progression and correlates with outcome.

Da Forno PD, Pringle JH, Hutchinson P, Osborn J, Huang Q, Potter L, Hancox RA, Fletcher A, Saldanha GS.

Clin Cancer Res. 2008 Sep 15;14(18):5825-32. doi: 10.1158/1078-0432.CCR-07-5104.

12.

Methylation and loss of Secreted Frizzled-Related Protein 3 enhances melanoma cell migration and invasion.

Ekström EJ, Sherwood V, Andersson T.

PLoS One. 2011 Apr 8;6(4):e18674. doi: 10.1371/journal.pone.0018674.

13.

A spoonful of sugar makes the melanoma go: the role of heparan sulfate proteoglycans in melanoma metastasis.

O'Connell MP, Weeraratna AT.

Pigment Cell Melanoma Res. 2011 Dec;24(6):1133-47. doi: 10.1111/j.1755-148X.2011.00918.x. Epub 2011 Nov 2. Review.

PMID:
21978367
14.

Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.

Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W 3rd, Becker KG, Kossenkov AV, Frederick DT, Flaherty KT, Xu X, Herlyn M, Murphy ME, Weeraratna AT.

Pigment Cell Melanoma Res. 2015 Mar;28(2):184-95. doi: 10.1111/pcmr.12330. Epub 2014 Dec 29.

15.

Syndecans reside in sphingomyelin-enriched low-density fractions of the plasma membrane isolated from a parathyroid cell line.

Podyma-Inoue KA, Hara-Yokoyama M, Shinomura T, Kimura T, Yanagishita M.

PLoS One. 2012;7(3):e32351. doi: 10.1371/journal.pone.0032351. Epub 2012 Mar 1.

16.

Wnt5a is strongly expressed at the leading edge in non-melanoma skin cancer, forming active gradients, while canonical Wnt signalling is repressed.

Pourreyron C, Reilly L, Proby C, Panteleyev A, Fleming C, McLean K, South AP, Foerster J.

PLoS One. 2012;7(2):e31827. doi: 10.1371/journal.pone.0031827. Epub 2012 Feb 22.

17.

Assaying Wnt5A-mediated invasion in melanoma cells.

O'Connell MP, French AD, Leotlela PD, Weeraratna AT.

Methods Mol Biol. 2008;468:243-53. doi: 10.1007/978-1-59745-249-6_19.

18.

Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation.

Dissanayake SK, Olkhanud PB, O'Connell MP, Carter A, French AD, Camilli TC, Emeche CD, Hewitt KJ, Rosenthal DT, Leotlela PD, Wade MS, Yang SW, Brant L, Nickoloff BJ, Messina JL, Biragyn A, Hoek KS, Taub DD, Longo DL, Sondak VK, Hewitt SM, Weeraratna AT.

Cancer Res. 2008 Dec 15;68(24):10205-14. doi: 10.1158/0008-5472.CAN-08-2149.

19.

WNT5A encodes two isoforms with distinct functions in cancers.

Bauer M, Bénard J, Gaasterland T, Willert K, Cappellen D.

PLoS One. 2013 Nov 18;8(11):e80526. doi: 10.1371/journal.pone.0080526. eCollection 2013.

20.

Laminin gamma2 mediates Wnt5a-induced invasion of gastric cancer cells.

Yamamoto H, Kitadai Y, Yamamoto H, Oue N, Ohdan H, Yasui W, Kikuchi A.

Gastroenterology. 2009 Jul;137(1):242-52, 252.e1-6.

PMID:
19582886

Supplemental Content

Support Center